
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon has demonstrated a robust growth trajectory, with gross business awards increasing by 11% on a sequential basis, fueled by significant partnerships with both biotech and large pharmaceutical clients. The company has also successfully met or exceeded financial targets related to its PRA acquisition, positioning itself well amid funding environment uncertainties and a favorable client mix. Additionally, Icon's improved win rate in the clinical trial sector indicates a strong ability to capitalize on the expanding market for contract research organizations.
Bears say
Icon's stock outlook is negatively influenced by a revision in EBITDA margin expectations, which have fallen to the high-19% range from previous projections of around 20% for both the current year and 2025. The company faces significant downside risks, including potential slowdowns in clinical trial activity due to pharmaceutical reprioritizations, uncertainties in biotech funding, and challenges in achieving revenue synergies from its PRA transaction. Additionally, broader economic factors such as inflation and a slowdown in pharmaceutical R&D spending further exacerbate the challenges Icon may encounter moving forward.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares